Oleksandra Tkachenko, Imed Helal, Dmitry Shchekochikhin and Robert W. Schrier Pages 12 - 20 ( 9 )
Autosomal dominant polycystic kidney disease is the most frequent life-threatening hereditary disease. Prognostic factors for progressive renal impairment have been identified such as gender, race, age, proteinuria, hematuria, hypertension. Hypertension is the only risk factor for renal dysfunction in autosomal dominant polycystic kidney disease, which is presently treatable. Better understanding of the pathophysiology of hypertension will help in defining appropriate interventions. The renin-angiotensin-aldosterone-system is the pivotal factor in the pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Basic research and clinical studies in autosomal dominant polycystic kidney disease implicated activation of the renin-angiotensin-aldosterone-system. Therapy of hypertension in autosomal dominant polycystic kidney disease with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker has the potential to prevent cardiovascular complications and slow the progression of renal disease. The results of two large multicenter double-blind placebo controlled randomized clinical trials (the HALT-PKD trials) possibly will elucidate the beneficial effects of the renin-angiotensin-aldosterone-system inhibition in autosomal dominant polycystic kidney disease.
Autosomal dominant polycystic kidney disease, renin-angiotensin-aldosterone-system, hypertension, sympathetic nervous system, angiotensin-converting enzyme inhibitors
University of Colorado Denver, Division of Renal Diseases and Hypertension, Box C-281. 1270 East 19th. RC2 7th floor Room 7001, Aurora, Colorado, 80045, USA.